Clinitech Lab (544220)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 24.51% and profit growth of 36.36% show strong momentum
• PEG of 0.70 suggests growth is not fully reflected in the P/E of 21.36
• Piotroski F-Score of 7/9 points to decent fundamental health
• Small ₹10 crore market cap offers niche upside in healthcare services

Concerns

• ROCE of only 8.15% indicates weak return on capital employed
• Latest quarter net profit of ₹0 Cr raises questions about earnings quality
• Zero dividend yield and no promoter holding data reduce transparency
• Insufficient data: no book value, debt/equity, or 52-week range to assess safety

AI Analysis

At heart, I’m not buying a ticker; I’m buying a business. Clinitech Lab, at ₹44 and ₹10 crore market cap, is a microcap healthcare service provider. The headline numbers look encouraging: sales grew 24.51%, profit grew 36.36%, and the P/E is 21.36. A PEG of 0.70 tells me the market isn’t fully pricing in that growth. The Piotroski F-Score of 7 out of 9 also suggests the company is reasonably sound on operating efficiency and capital structure. But I must stop and ask: what is the moat? I see nothing here that gives Clinitech pricing power or protection from competition. ROCE of 8.15% is far below what I demand; a good business should earn notably more on capital than this. Without book value, debt/equity, and promoter holding data, I am flying blind. Graham would insist on margin of safety; a ₹10 crore company with zero dividend and a latest quarter net profit of roughly ₹0 crore offers little safety. It may be a fast grower in a promising healthcare services sector, but growth without durable returns is just hope. I would not classify it as an investment; it is a small speculation. If the company can convert sales growth into real earnings, improve ROCE toward 15% plus, and reveal clean financials, I’d become more interested. Until then, I’d let the numbers do more talking. For a retail investor, the lack of transparent data is a red flag. It may work out, but it’s not a bet I can make with confidence. I’d watch it, not marry it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer